
Certara, Inc. — Investor Relations & Filings
Certara, Inc. is a company that accelerates drug discovery and development through the use of proprietary biosimulation software, technology, and expert services. It provides an end-to-end platform that supports clients across the entire drug development lifecycle, from discovery and preclinical research to clinical trials, regulatory submissions, and market access. The company's solutions leverage predictive simulation, data-driven modeling, and advanced analytics to help pharmaceutical and biotechnology organizations optimize trial design, justify dosing decisions, and navigate regulatory requirements. Key software products include Simcyp, Phoenix, and Pinnacle 21. Certara's offerings are designed to de-risk development, enhance efficiency, and increase the likelihood of bringing new medicines to patients.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - Certara, Inc. (0001827090) (Filer) | 2026-04-22 | English | |
| ARS - Certara, Inc. (0001827090) (Filer) | 2026-04-03 | English | |
| DEF 14A - Certara, Inc. (0001827090) (Filer) | 2026-04-03 | English | |
| 4 - CERTARA, INC. (0001827090) (Filer) | 2026-03-02 | English | |
| 10-K - CERTARA, INC. (0001827090) (Filer) | 2026-02-26 | English | |
| 8-K - CERTARA, INC. (0001827090) (Filer) | 2026-02-26 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
7 filings
| |||||
| 35223149 | 8-K - Certara, Inc. (0001827090) (Filer) | 2026-04-22 | English | ||
| 33256151 | ARS - Certara, Inc. (0001827090) (Filer) | 2026-04-03 | English | ||
| 33255090 | DEF 14A - Certara, Inc. (0001827090) (Filer) | 2026-04-03 | English | ||
| 32899219 | 4 - CERTARA, INC. (0001827090) (Filer) | 2026-03-02 | English | ||
| 32899221 | 10-K - CERTARA, INC. (0001827090) (Filer) | 2026-02-26 | English | ||
| 32899220 | 8-K - CERTARA, INC. (0001827090) (Filer) | 2026-02-26 | English | ||
| 13319431 | Director's Dealing 2026 | 2026-01-12 | English | ||
|
2025
8 filings
| |||||
| 13319432 | FORM 8-K | 2025-12-11 | English | ||
| 13319433 | Major Shareholding Notification 2025 | 2025-11-25 | English | ||
| 13319434 | Major Shareholding Notification 2025 | 2025-11-13 | English | ||
| 13319435 | Director's Dealing 2025 | 2025-11-12 | English | ||
| 13319436 | 10-Q | 2025-11-06 | English | ||
| 13319437 | 8-K | 2025-11-06 | English | ||
| 13319438 | FORM 8-K | 2025-10-16 | English | ||
| 13319439 | Major Shareholding Notification 2025 | 2025-10-09 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Oncocross Co.,Ltd.
An AI biotechnology firm that develops drugs by predicting …
|
382150 | KR | Professional, scientific and te… |
|
ONCODESIGN
Develops therapeutic and diagnostic solutions for resistant…
|
ALONC | FR | Professional, scientific and te… |
|
Onco-Innovations
Biotechnology firm developing next-generation cancer therap…
|
ONCO | CA | Professional, scientific and te… |
|
OncoTherapy Science, Inc.
Biopharmaceutical company researching and developing novel …
|
4564 | JP | Professional, scientific and te… |
|
Optipharm.CO.,LTD
Develops animal health solutions, biotherapeutics, and xeno…
|
153710 | KR | Professional, scientific and te… |
|
ORAGENICS INC
Biotechnology company developing intranasal therapeutics fo…
|
OGEN | US | Professional, scientific and te… |
|
ORGANOIDSCIENCES LTD.
Develops organoid-based technologies for drug development a…
|
476040 | KR | Professional, scientific and te… |
|
Orum Therapeutics, Inc.
Clinical-stage biotech developing degrader-antibody conjuga…
|
475830 | KR | Professional, scientific and te… |
|
OSR Holdings, Inc.
A healthcare holding company acquiring and developing innov…
|
OSRH | US | Professional, scientific and te… |
|
OS Therapies Inc
Clinical-stage immunotherapy company developing treatments …
|
OSTX | US | Professional, scientific and te… |
Certara, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/31699/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=31699 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=31699 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=31699 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 31699}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Certara, Inc. (id: 31699)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.